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Data from randomized-controlled trials of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) in patients with 
coronary artery disease (CAD) but no clinical evidence of heart failure are inconclusive. This study was undertaken to more clearly define the role of 
these agents in both the acute and chronic CAD setting, in patients without clinical evidence of heart failure.
We selected randomized-controlled trials with ACEi or ARB as the single intervention, focusing on patients with CAD including patients with left 
ventricular dysfunction but no clinical symptoms of heart failure according to ACC heart failure criteria. The MEDLINE database was searched for all 
publications between 1/1/1980 and 12/31/2012 with searched terms including angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers, coronary artery disease, cardiovascular events, and myocardial infarction. The publications were filtered for randomized-controlled trials, 
multicenter studies, controlled clinical trials, and adult human subjects. A total of 1,553 publications were screened, of which 17 studies (13 ACEi 
and 4 ARB) met the inclusion criteria for a total of 84,220 randomized patients followed for a mean of 36 months. We evaluated the endpoints of 
all-cause mortality, cardiovascular (CV) mortality, non-fatal myocardial infarction (MI), and stroke.
Of the 17 trials, 3 included were post-MI studies and 2 were post-revascularization studies. Treatment with ACEi and ARB across the 17 trials 
was associated with decreased CV mortality (RR 0.85; 95% CI, 0.78-0.93) and all-cause mortality (RR 0.92; 95% CI, 0.86-0.98). No statistically 
significant reduction in other endpoints, including MI (RR 0.97; 95% CI 0.91-1.04) and stroke (RR 0.91; 95% CI 0.80-1.03) was demonstrated. From 
the 4 ARB trials, stroke was the only endpoint with a statistically significant reduction (RR 0.93; 95% CI 0.87-0.99). But all remaining endpoints 
trended toward benefit in the intervention arm.
ACEi and ARB reduce both CV mortality and all-cause mortality in all CAD patients without clinical evidence of heart failure. This is true regardless of 
CAD acuity.
